Quantifying insulin receptor isoform expression in FFPE breast tumors
about
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentEpithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?Obesity and cancer pathogenesis.Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Aberrant liver insulin receptor isoform a expression normalises with remission of type 2 diabetes after gastric bypass surgery.Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsRidaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.Development of a Quantitative PCR Assay for Detection of Human Insulin-Like Growth Factor Receptor and Insulin Receptor Isoforms.Differential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma.Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cellsMetabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways.Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation.Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer.Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatmeInsulin and IGFs in obesity-related breast cancer.Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyInsulin Receptor Isoforms in Physiology and Disease: An Updated View.
P2860
Q26798408-047A6A29-1EC8-40E8-8348-0BA0174DFAA7Q28087055-350D81CB-BA14-42AC-9927-4F7980EEEE4BQ30361298-153892EE-5CAA-4A47-A612-8B3ECDB1BBD4Q33756414-D527EC3F-335E-4C80-911C-CB74A3CC2C23Q34336988-9DA6E062-2AB9-43D9-A663-9525B3551ACBQ35152265-F51956DA-2395-491E-9C5D-0284CD94ED3EQ35226507-C65F3D19-4C28-4B44-825D-C503FEF64CCDQ36169793-B2BD4701-9E83-4492-9A43-3B5F19790052Q36753844-B59F4016-DD5D-461A-9E03-066EF2A2CB28Q37057923-82278AAB-F9F8-4431-9B51-19E10FF0B7CBQ37171068-DFB85437-7A8F-4C03-B388-7FAB5D42D517Q37191427-AC8759EF-C8ED-4F2B-B77A-B7DD74046C2BQ37193406-A8011509-9E93-46D5-81C6-C5C138FC4413Q37386140-78B7E142-77AF-44AB-A9F3-09D9BD7B963BQ37577156-2807DDE3-6B67-434A-8A2F-09D8825BDFCCQ37705915-02FF3184-0203-4B96-A513-A1CDD328D0E6Q38155073-89C62BA5-8EDF-4C24-804F-DDB9366284CAQ41302136-D89E4295-A5F0-48CC-8922-F01F8DCB5528Q47668280-7BBE6BAE-CFB9-4187-8837-4891F409E90F
P2860
Quantifying insulin receptor isoform expression in FFPE breast tumors
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Quantifying insulin receptor isoform expression in FFPE breast tumors
@ast
Quantifying insulin receptor isoform expression in FFPE breast tumors
@en
type
label
Quantifying insulin receptor isoform expression in FFPE breast tumors
@ast
Quantifying insulin receptor isoform expression in FFPE breast tumors
@en
prefLabel
Quantifying insulin receptor isoform expression in FFPE breast tumors
@ast
Quantifying insulin receptor isoform expression in FFPE breast tumors
@en
P2093
P2860
P1476
Quantifying insulin receptor isoform expression in FFPE breast tumors
@en
P2093
Carol Reynolds
Paul Haluska
S John Weroha
Sean C Harrington
Vera J Suman
Wilma L Lingle
P2860
P304
P356
10.1016/J.GHIR.2012.04.001
P577
2012-04-30T00:00:00Z